An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy

Area of Science:

• Biotechnology
• Immunotherapy
• Synthetic Biology

Background:

• T-cell immunotherapy shows promise for cancer treatment but is limited in solid tumors due to the immunosuppressive tumor microenvironment.
• Engineered T cells face challenges with sustained activity and control within the tumor microenvironment.

Purpose of the Study:

• To develop a synthetic optogenetic circuit for on-demand control of engineered T cells.
• To enhance the therapeutic efficiency of T-cell immunotherapy in solid tumors.

Main Methods:

• Designed and synthesized a blue-light inducible optogenetic circuit for transgene expression.
• Investigated blue light-triggered gene expression using luciferase assays, qPCR, and ELISA.
• Assessed T-cell cytotoxicity, proliferation, and in vivo anti-tumor activity in a human hepatocellular carcinoma xenograft model.

Main Results:

• Blue light stimulation enabled spatiotemporal control of cytokine gene expression (IL2, IL15, TNF-α) in engineered cells and primary T cells.
• Optogenetic engineering significantly enhanced T-cell expansion and cytolytic activity upon light irradiation.
• Light-activated T cells demonstrated high-efficiency elimination of hepatocellular carcinoma xenografts.

Conclusions:

• An engineered, remotely controlled T-cell system for solid tumor treatment was developed.
• This optogenetic strategy offers a potential approach to overcome limitations of current immune cell therapy for solid tumors.